Compare Intuit Inc. (INTU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Tango Therapeutics Inc. — how do they compare? Intuit Inc. trades at $309.58 (market cap $80.56B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Intuit Inc. is far larger — about 21.5× Tango Therapeutics Inc.'s market cap, and Intuit Inc. pays a 1.83% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 67 Days and Tango Therapeutics Inc. for 0 Days on average.
| INTU | TNGX | |
|---|---|---|
Market Cap | $80.56B | $3.75B |
Volume | 3,646,799 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $683.39 | $32.90 |
52-Week Low | $255.07 | $7.50 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $81.78B | $2.77B |
Dividend Yield | 1.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $305.99, up 1.07% with strong earnings momentum after beating Q4 2025 and Q1-Q2 2026 EPS estimates. The stock shows bullish technical signals with support at $302 and resistance at $312. Fundamentally, revenue grew to $18.83B in 2025 with a robust 21.29% net margin, while valuation ratios like P/E of 18.31 appear reasonable. Recent news highlights growth in QuickBooks monetization and AI initiatives, though class action lawsuits create near-term uncertainty.
Outlook remains positive with analyst consensus target of $379.68 (24% upside) and 60% buy ratings. Key opportunities include sustained revenue growth and margin expansion, while risks involve legal overhangs and competitive pressures in financial software. The stock offers attractive fundamentals but requires monitoring of lawsuit developments.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
